Boehringer Ingelheim Corporation Release: Pivotal Phase III Results for Afatinib* in Lung Cancer to be Presented at American Society of Clinical Oncology 2012

NGELHEIM, Germany--(BUSINESS WIRE)-- Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012. LUX-Lung 3, which compares afatinib to standard platinum based chemotherapy, is the largest Phase III trial in first-line EGFR mutation positive, advanced, metastatic non-small cell lung cancer (NSCLC) patients.1 LUX-Lung 3 is also the first study using pemetrexed/cisplatin as a comparator.